PriMera Scientific Surgical
Research and Practice
Volume 7 Issue 5 May 2026
ISSN: 2836-0028

PriMera Scientific Publications

From Bench to Bedside: Bridging the Gap in Translational Biochemistry

Type: Editorial
Received: April 14, 2026
Published: April 29, 2026

Citation:
Myrene Roselyn D'souza. "From Bench to Bedside: Bridging the Gap in Translational Biochemistry". PriMera Scientific Surgical Research and Practice 7.5 (2026): 01-03.

Myrene Roselyn D'souza*

Department of Biochemistry, School of Natural and Applied Sciences, Mount Carmel College Autonomous, Bengaluru, India

***Corresponding Author:** Myrene Roselyn D'souza, Department of Biochemistry, School of Natural and Applied Sciences, Mount Carmel College Autonomous, Bengaluru, India.

Modern biochemistry is able to redefine patient care, not only in the sense of how it can be discovered, but also how it can be applied to redefine patient care. Still, despite the remarkable breakthroughs in the fields of molecular biology, genomics and biochemical technology, there is still an endemic absence of connections between laboratory research and clinical practice. Even the scientific breakthroughs can still be too long to effectively translate scientific discovery into a workable health intervention, raising urgent questions about the efficiency and attention of new biomedical research (El-Tanani et al., 2024).

In its simplest form, the objective of translational biochemistry purportedly is an intermediary - to convert the mechanistic knowledge into diagnostics, therapy and prevention. The reality of the situation is much more complex. In numerous instances, good preclinical results are not applicable to clinical trials. This has also come to be known as the "valley of death" and it points out the inadequacies of the current models of experiments which in most cases cannot deliver the biological complexity of human disease (Butler, 2008). The use of simplified in vitro models and animal models, despite being necessary, overestimates therapeutic effects and underestimates toxicity.

Not less worrying is the disaggregation of the research ecosystem. Basic scientists and clinicians are also siloed in their interactions and priorities and rarely interact or have conflicting priorities (Lau et al., 2024). Whereas the laboratory scientists are concerned with the mechanisms, clinicians are patient centered. The inability to continuously collaborate on these areas is also a contributing factor that contributes to the translational gap. There must exist a bridge that must be filled by more than interdisciplinary conversation; there must be a structural connection between research and clinical practice.

The obstacle has been augmented by financial and regulatory barriers. Translational research is a resource-intensive undertaking, and one of the financial burdens is the clinical trials. Numerous discoveries have been discarded following a lack of funding, especially when Phase II is changed to Phase III trials. At the same time, regulatory systems, as much as required to promote safety and efficacy, tend to create delays that can slow down the rapid innovation. Maintaining a balance between strict control and quicker translation is an urgent question (Zhou et al., 2025).

Nevertheless, these problems notwithstanding, the field of translational biochemistry has already shown the transformational potential. The case of precision medicine, which was created by the in-

novations in genomics and molecular profiling, is an example of the successful introduction of bench research into the clinic. Oncology treatments, such as targeted therapies, have reshaped the treatment processes by targeting particular molecular pathways, as opposed to generalized ones. Equally, the discovery of biochemical biomarkers has increased the ability to detect diseases at an early stage and prognostic value (El-Tanani et al., 2024). The above success highlights the possibilities of effective translational pathways.

The translational gap could be narrowed in the future with the promising future of the integration of new technologies. Machine learning and AI can process more complex biochemical data and identify new drug targets and achieve more accurate therapeutic responses than previously. New technologies such as organ-on-a-chip models and 3D cell cultures provide more physiologically relevant models and improve the predictive validity of preclinical studies.

Nevertheless, the level of technological progress is not enough. This is a paradigm shift that is more collaborative, patient-centered research and translational accountable. The establishment of special translational research centers, the establishment of a connection between the academic community and the industry and the alignment of the funding mechanisms with the goals of translational research are significant steps in this direction. Additionally, patient views included in the research design will make the scientific work clinical.

The centre of translation work should also be centred on moral aspects. Informed consent, protection of patient information, and fair access to new medications should be encouraged to make sure that people will trust the new treatments. As the sphere of translational biochemistry continuously evolves, it must be able to work in a system that does not sacrifice innovation, but at the same time, responsibility.

In conclusion, narrowing the bench-bedside gap is not only a scientific issue but also a moral issue. Biochemical research can be assessed in terms of its true value to improve human health. The vision of translational biochemistry can be achieved by overcoming current obstacles and providing a more integrated and collaborative research ecosystem. It is now time to go beyond discovery as an end to a new era where each scientific discovery has a well-defined and intended route to patient care.



Figure: Translational biochemistry flowchart of the pathway between laboratory research (bench) to clinical implementation (bedside). The figure summarizes the main steps, such as basic science, drug discovery, preclinical research and clinical trials, and major obstacles including regulatory issues, funding constraints, and disciplinary silos. It also illustrates the incorporation of these elements into translational biomedicine to make it possible to achieve the results of targeted therapies, biomarker development, precision medicine, and better patient care (Created using OpenAI, 2026).

References

1. Butler D. "Translational research: crossing the valley of death". Nature 453.7197 (2008): 840-842.
2. El-Tanani M., et al. "Bridging the gap: From petri dish to patient - Advancements in translational drug discovery". Heliyon 11.1 (2024): e41317.
3. Lau RS., et al. "Siloed mentality, health system suboptimization and the healthcare symphony: a Canadian perspective". Health research policy and systems 22.1 (2024): 87.
4. Zhou Y., et al. "Dynamic clinical trial success rates for drugs in the 21st century". Nature Communications 16 (2025): 9537.